D. A. Vyzhigin
Research Subjects
D. A. Vyzhigin has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Elena Yu. Shupenina
Russian University of Medicine
11 shared publications - Yury A. Vasyuk
Russian University of Medicine
10 shared publications - E. O. Novosel
Russian University of Medicine
9 shared publications A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
2 shared publications- Dar'JA A. Filonenko
Loginov Moscow Clinical Scientific Center
2 shared publications - Dmitry Anatolievich Astakhov
Russian University of Medicine
2 shared publications
Latest Publications
- 7 September 2026
- Published by Bionika Media in Therapy
- Vol. 6_2026
Heart rhythm and conduction impairments in cancer patients: Clinical and functional peculiarities
- 7 September 2026
- Published by Bionika Media in Therapy
- Vol. 6_2026
Heart rhythm and conduction impairments in cancer patients: Clinical and functional peculiarities
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (3)
Predicting cardiotoxicity of antitumor therapy: an easy way to point the right direction
Aim . To discuss a new method for predicting cardiovascular toxicity of chemotherapy and targeted therapy based on echocardiographic changes of left atrial volume index (LAVI). Material and methods . This prospective observational study was conducted at the Department of Hospital Internal Medicine № 1 of the Russian University of Medicine. The study included 149 cancer patients aged 18 to 80 years receiving antitumor treatment and at high and very high risk of cardiovascular toxicity, as defined by the Mayo Clinic (USA) score. All study participants underwent a clinical and paraclinical examination, including a patient history and complaint collection, physical examination, 12-lead electrocardiography (ECG), two-dimensional echocardiography to determine left ventricular systolic global longitudinal strain, 12-lead 24-hour ECG monitoring, and 24-hour blood pressure monitoring before the start of antitumor therapy and at 1, 3, 6, 9, and 12 months after the start of antitumor treatment. Throughout the monitoring period, the emergence of previously absent cardiovascular lesions was monitored. Results . During the 12-month follow-up, 76 (51%) study participants were found to have various manifestations of cardiovascular toxicity. An analysis of echocardiography results in patients with developed cardiovascular complications revealed left atrial dilation with an increase in LAVI to >34 ml/m 2 . ROC analysis and the Kaplan-Meier estimator revealed that an LAVI ≥34 ml/m 2 corresponds to an increased risk of cardiovascular complications, including death in cancer patients. Conclusion . The obtained results provide internists, cardiologists, and oncologists with an easily accessible and reproducible echocardiography indicator (LAVI) that can accurately cardiovascular toxicity after antitumor therapy. Based on the above, the authors submitted an application to the Federal Institute of Industrial Property and received a patent for the invention.
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (3)
Predicting cardiotoxicity of antitumor therapy: an easy way to point the right direction
Aim . To discuss a new method for predicting cardiovascular toxicity of chemotherapy and targeted therapy based on echocardiographic changes of left atrial volume index (LAVI). Material and methods . This prospective observational study was conducted at the Department of Hospital Internal Medicine № 1 of the Russian University of Medicine. The study included 149 cancer patients aged 18 to 80 years receiving antitumor treatment and at high and very high risk of cardiovascular toxicity, as defined by the Mayo Clinic (USA) score. All study participants underwent a clinical and paraclinical examination, including a patient history and complaint collection, physical examination, 12-lead electrocardiography (ECG), two-dimensional echocardiography to determine left ventricular systolic global longitudinal strain, 12-lead 24-hour ECG monitoring, and 24-hour blood pressure monitoring before the start of antitumor therapy and at 1, 3, 6, 9, and 12 months after the start of antitumor treatment. Throughout the monitoring period, the emergence of previously absent cardiovascular lesions was monitored. Results . During the 12-month follow-up, 76 (51%) study participants were found to have various manifestations of cardiovascular toxicity. An analysis of echocardiography results in patients with developed cardiovascular complications revealed left atrial dilation with an increase in LAVI to >34 ml/m 2 . ROC analysis and the Kaplan-Meier estimator revealed that an LAVI ≥34 ml/m 2 corresponds to an increased risk of cardiovascular complications, including death in cancer patients. Conclusion . The obtained results provide internists, cardiologists, and oncologists with an easily accessible and reproducible echocardiography indicator (LAVI) that can accurately cardiovascular toxicity after antitumor therapy. Based on the above, the authors submitted an application to the Federal Institute of Industrial Property and received a patent for the invention.
- 1 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (11) , 86-93
Predictors of arrhythmia and adverse outcomes in cancer patients during antitumor treatment
Malignancies are one of the leading causes of death in the world. Cardiotoxicity, including high-grade heart rhythm disturbances (HRD), is the leading cause of death in patients not directly associated with malignancies. Objective. To determine the predictors of arrhythmias and adverse outcomes in patients with cancer during and after antitumor treatment. Materials and methods. A comparative retrospective and prospective non-randomized observational study was conducted. The sample included patients with cancer (n=101) aged 25 to 80 years, with a high and very high risk of cardiotoxicity. The test group included 49 cancer patients with HRDs; 35 of them were included retrospectively, after the onset of arrhythmias, and 14 patients with HRDs were identified during prospective observation. The control group consisted of 52 cancer patients without arrhythmias during the observation. All study participants underwent a physical examination, an electrocardiogram (ECG), an echocardiogram in two-dimensional (2D) and three-dimensional (3D) modes with the calculation of global longitudinal strain of the left ventricle (GLSLV) and left atrium (GLSLA), and 24-hour 12-channel ECG monitoring. In some patients (n=68), the biomarkers were measured: cardiac-specific troponin I (TnI), N-terminal Brain Natriuretic ProPeptide (N-t proBNP), soluble suppression of tumorigenicity 2 (sST2), and myeloperoxidase. A telephone survey was conducted 24 months after enrollment. Results. Reduction of GLSLA in 2D mode in the filling phase <24% and GLSLV in 3D mode 186.1 ng/L, according to the ROC analysis, had the best predictive ability regarding the development of HRDs. Male sex, the presence of atrial fibrillation, and the use of antimetabolites were the most significant prognostic factors for adverse outcomes. LA dysfunction has been observed to be a predictor of arrhythmias (increase in indexed left atrial volume ≥40 mL/m2). Some publications show a decrease in patient survival associated with the use of antimetabolites in the antitumor treatment regimen. Conclusion. In addition to the standard echocardiographic examination in patients with cancer, it is recommended to assess several indicators of myocardial strain (the global longitudinal strain of the left ventricle in 3D mode, the longitudinal strain of the left atrium in the filling phase) and the level of the N-t proBNP.
- 1 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (11) , 86-93
Predictors of arrhythmia and adverse outcomes in cancer patients during antitumor treatment
Malignancies are one of the leading causes of death in the world. Cardiotoxicity, including high-grade heart rhythm disturbances (HRD), is the leading cause of death in patients not directly associated with malignancies. Objective. To determine the predictors of arrhythmias and adverse outcomes in patients with cancer during and after antitumor treatment. Materials and methods. A comparative retrospective and prospective non-randomized observational study was conducted. The sample included patients with cancer (n=101) aged 25 to 80 years, with a high and very high risk of cardiotoxicity. The test group included 49 cancer patients with HRDs; 35 of them were included retrospectively, after the onset of arrhythmias, and 14 patients with HRDs were identified during prospective observation. The control group consisted of 52 cancer patients without arrhythmias during the observation. All study participants underwent a physical examination, an electrocardiogram (ECG), an echocardiogram in two-dimensional (2D) and three-dimensional (3D) modes with the calculation of global longitudinal strain of the left ventricle (GLSLV) and left atrium (GLSLA), and 24-hour 12-channel ECG monitoring. In some patients (n=68), the biomarkers were measured: cardiac-specific troponin I (TnI), N-terminal Brain Natriuretic ProPeptide (N-t proBNP), soluble suppression of tumorigenicity 2 (sST2), and myeloperoxidase. A telephone survey was conducted 24 months after enrollment. Results. Reduction of GLSLA in 2D mode in the filling phase <24% and GLSLV in 3D mode 186.1 ng/L, according to the ROC analysis, had the best predictive ability regarding the development of HRDs. Male sex, the presence of atrial fibrillation, and the use of antimetabolites were the most significant prognostic factors for adverse outcomes. LA dysfunction has been observed to be a predictor of arrhythmias (increase in indexed left atrial volume ≥40 mL/m2). Some publications show a decrease in patient survival associated with the use of antimetabolites in the antitumor treatment regimen. Conclusion. In addition to the standard echocardiographic examination in patients with cancer, it is recommended to assess several indicators of myocardial strain (the global longitudinal strain of the left ventricle in 3D mode, the longitudinal strain of the left atrium in the filling phase) and the level of the N-t proBNP.
- Open Access
- 10 September 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (8) , 12-21
Results of a Single-Center Prospective Observational Study: How to Take Care of the Heart of a Cancer Patient
Aim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine. The comparison group consisted of 66 patients who refused cardioprotective drugs or had intolerance to them. All patients underwent 24-hour ambulatory blood pressure monitoring (ABPM) and multibiomarker analysis, including measurements of troponin I (TnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), myeloperoxidase (MPO), soluble tumor suppressor type 2 (sST2), and two-dimensional echocardiography (EchoCG) with assessment of left ventricular global longitudinal systolic strain (LV GLS) before chemotherapy and 1, 3, 6, 9, and 12 months after the start of cardiotoxic antitumor therapy. Results In patients of the comparison group already at 6 months, the left atrial volume index (LAVI) was significantly increased, and the left ventricular end-diastolic volume index (LVEDVi) showed a tendency towards an increase reaching a significant difference by 9 months of observation. In the main group, these parameters did not significantly change during the study. At the last stage of observation, there were statistically significant differences in LAVI and LVEDVi between the compared groups. The dynamics of LV GLS in the compared groups showed multidirectional changes. In the main group, this parameter remained virtually unchanged while in the comparison group, it decreased by ≥15% in 13 patients and reached a statistically significant difference. Clinically pronounced cardiotoxicity and a decrease in the left ventricular ejection fraction (LVEF) developed in 7 of these patients. During the antitumor treatment, the concentrations of the biomarkers remained within the reference values, with the exception of TnI. The greatest differences between the groups were noted in the analysis of mortality. Thus, by the final visit, 13.1% of patients had died in the main group while in the comparison group, mortality was almost two times higher and reached 22.7%. Conclusion The study demonstrated clinical effectiveness of the cardioprotective therapy in cancer patients at high and very high risk of cardiotoxicity. The patients who did not receive the primary drug prevention of cardiovascular toxicity had a statistically significant impairment of the LV systolic function, an increased number of developed complications, and a higher mortality.
- 10 September 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (8) , 12-21
Open AccessResults of a Single-Center Prospective Observational Study: How to Take Care of the Heart of a Cancer Patient
Aim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine. The comparison group consisted of 66 patients who refused cardioprotective drugs or had intolerance to them. All patients underwent 24-hour ambulatory blood pressure monitoring (ABPM) and multibiomarker analysis, including measurements of troponin I (TnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), myeloperoxidase (MPO), soluble tumor suppressor type 2 (sST2), and two-dimensional echocardiography (EchoCG) with assessment of left ventricular global longitudinal systolic strain (LV GLS) before chemotherapy and 1, 3, 6, 9, and 12 months after the start of cardiotoxic antitumor therapy. Results In patients of the comparison group already at 6 months, the left atrial volume index (LAVI) was significantly increased, and the left ventricular end-diastolic volume index (LVEDVi) showed a tendency towards an increase reaching a significant difference by 9 months of observation. In the main group, these parameters did not significantly change during the study. At the last stage of observation, there were statistically significant differences in LAVI and LVEDVi between the compared groups. The dynamics of LV GLS in the compared groups showed multidirectional changes. In the main group, this parameter remained virtually unchanged while in the comparison group, it decreased by ≥15% in 13 patients and reached a statistically significant difference. Clinically pronounced cardiotoxicity and a decrease in the left ventricular ejection fraction (LVEF) developed in 7 of these patients. During the antitumor treatment, the concentrations of the biomarkers remained within the reference values, with the exception of TnI. The greatest differences between the groups were noted in the analysis of mortality. Thus, by the final visit, 13.1% of patients had died in the main group while in the comparison group, mortality was almost two times higher and reached 22.7%. Conclusion The study demonstrated clinical effectiveness of the cardioprotective therapy in cancer patients at high and very high risk of cardiotoxicity. The patients who did not receive the primary drug prevention of cardiovascular toxicity had a statistically significant impairment of the LV systolic function, an increased number of developed complications, and a higher mortality.
- Open Access
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 209-216
New opportunities for preclinical diagnostics of antitumor therapy cardiotoxicity: results of an observational study
Aim. To study new possibilities of the potential of speckle tracking echocardiography for detecting early subclinical cardiotoxicity of chemo- and targeted therapy.Material and methods. 150 patients with a verified oncological diagnosis, with a very high or high risk of cardiotoxicity, determined by the Mayo Clinic scale, were included in the prospective observational study at the Department of Hospital Therapy No. 1 of the Russian Medical University of the Ministry of Health of Russia in 2021-2023. All enrolled patients were recommended to take a fixed combination of the ACE inhibitor perindopril and the beta-blocker bisoprolol (5+5 mg) 5-7 days before the start of chemo-targeted therapy. Patients with a very high risk of cardiotoxicity who were diagnosed with ischemic chronic heart failure or stable coronary artery disease, or post-myocardial infarction, were additionally recommended to take long-acting trimetazidine OD at a dose of 80 mg once daily. At the second visit, the main group (n=84, receiving cardioprotective drugs) and the comparison group (n=66, not receiving cardioprotective drugs) were formed. All patients at the time of inclusion in the study, as well as 1, 3, 6, 9 and 12 months after the start of antitumor therapy, underwent the following assessment: collecting complaints, anamnesis data, physical examination, ECG registration in 12 standard leads, and a two-dimensional echocardiogram with the measurement of left ventricular (LV) global longitudinal strain (GLS).Results. Primary drug prophylaxis in cancer patients with high and very high risk of cardiotoxicity was associated with a 2.7-fold decrease in significant cardiovascular complications. The development of chronic heart failure in the main group was noted 7 times less frequently than in the comparison group (n=1 (1.2%) vs n=7 (10.6%), pConclusion. The detection of typical changes in local longitudinal strain should be considered as an early sign of cardiotoxicity with a subsequent change in treatment tactics: temporary or permanent withdrawal of the drugs that caused cardiovascular complications, the appointment of cardioprotective therapy with ACE inhibitors, beta-adrenergic blockers and myocardial cytoprotectors.
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 209-216
Open AccessNew opportunities for preclinical diagnostics of antitumor therapy cardiotoxicity: results of an observational study
Aim. To study new possibilities of the potential of speckle tracking echocardiography for detecting early subclinical cardiotoxicity of chemo- and targeted therapy.Material and methods. 150 patients with a verified oncological diagnosis, with a very high or high risk of cardiotoxicity, determined by the Mayo Clinic scale, were included in the prospective observational study at the Department of Hospital Therapy No. 1 of the Russian Medical University of the Ministry of Health of Russia in 2021-2023. All enrolled patients were recommended to take a fixed combination of the ACE inhibitor perindopril and the beta-blocker bisoprolol (5+5 mg) 5-7 days before the start of chemo-targeted therapy. Patients with a very high risk of cardiotoxicity who were diagnosed with ischemic chronic heart failure or stable coronary artery disease, or post-myocardial infarction, were additionally recommended to take long-acting trimetazidine OD at a dose of 80 mg once daily. At the second visit, the main group (n=84, receiving cardioprotective drugs) and the comparison group (n=66, not receiving cardioprotective drugs) were formed. All patients at the time of inclusion in the study, as well as 1, 3, 6, 9 and 12 months after the start of antitumor therapy, underwent the following assessment: collecting complaints, anamnesis data, physical examination, ECG registration in 12 standard leads, and a two-dimensional echocardiogram with the measurement of left ventricular (LV) global longitudinal strain (GLS).Results. Primary drug prophylaxis in cancer patients with high and very high risk of cardiotoxicity was associated with a 2.7-fold decrease in significant cardiovascular complications. The development of chronic heart failure in the main group was noted 7 times less frequently than in the comparison group (n=1 (1.2%) vs n=7 (10.6%), pConclusion. The detection of typical changes in local longitudinal strain should be considered as an early sign of cardiotoxicity with a subsequent change in treatment tactics: temporary or permanent withdrawal of the drugs that caused cardiovascular complications, the appointment of cardioprotective therapy with ACE inhibitors, beta-adrenergic blockers and myocardial cytoprotectors.
- Open Access
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 3-10
Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?
It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient’s clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 3-10
Open AccessDetermining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?
It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient’s clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.
- Open Access
- 21 January 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (2) , 4104
Premature coronary artery disease in a patient with a history of combined treatment for lymphogranulomatosis: a case report
Introduction. Cancer occupies one of the leading positions in the list of the most common death causes in the world. The widespread use of chemo-, targeted, immune and radiation therapy in clinical practice has increased the survival of cancer patients. However, the incidence of cardiotoxic complications of antitumor therapy has increased significantly, and they may manifest themselves many years after the onset of cancer remission. Brief description. We present a case of premature coronary artery disease (CAD) in a 40-year-old male patient, who underwent multiagent chemotherapy in combination with radiation therapy for mediastinal lymph nodes due to lymphogranulomatosis at the age of 22. In 2021, against the background of a stressful situation, the patient first noted a burning sensation in chest, which was relieved spontaneously, and an increase in blood pressure to 145/90 mm Hg. After visiting a cardiologist, a clinical, electrocardiographic and echocardiographic (at rest) examination was performed. However, no pathology was found, and therapy was not prescribed. Over the next 3 years, short-term squeezing pain in chest was periodically noted, occurring during fast walking, which was relieved when stopping. In April 2024, the patient was hospitalized in the cardiology department of the University Clinic of the N. A. Semashko Institute of Clinical Medicine of the Russian University of Medicine for an in-depth cardiological examination. Analysis of complaints and anamnestic data, clinical and paraclinical examination, made it possible to diagnose CAD, class III angina pectoris. This was regarded as a late manifestation of cardiotoxicity of chemotherapy in combination with radiation therapy to the mediastinal area, performed at the age of 22 for lymphogranulomatosis. Selective coronary angiography revealed multiple coronary stenoses. For myocardial revascularization, the patient was referred to the I. V. Davydovsky City Clinical Hospital, where 4 drug-eluting stents were inserted. Follow-up monitoring of the cardiovascular system was not carried out. When contacting a cardiologist with complaints typical for coronary insufficiency, CAD was not diagnosed. Conclusion. The presented case shows the difficulties in diagnosing long-term manifestations of cardiotoxicity in the form of premature CAD. It is necessary to conduct additional educational activities and introduce modern technological products to improve the effectiveness of primary prevention, diagnosis and treatment of cardiotoxicity of antitumor therapy.
- 21 January 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (2) , 4104
Open AccessPremature coronary artery disease in a patient with a history of combined treatment for lymphogranulomatosis: a case report
Introduction. Cancer occupies one of the leading positions in the list of the most common death causes in the world. The widespread use of chemo-, targeted, immune and radiation therapy in clinical practice has increased the survival of cancer patients. However, the incidence of cardiotoxic complications of antitumor therapy has increased significantly, and they may manifest themselves many years after the onset of cancer remission. Brief description. We present a case of premature coronary artery disease (CAD) in a 40-year-old male patient, who underwent multiagent chemotherapy in combination with radiation therapy for mediastinal lymph nodes due to lymphogranulomatosis at the age of 22. In 2021, against the background of a stressful situation, the patient first noted a burning sensation in chest, which was relieved spontaneously, and an increase in blood pressure to 145/90 mm Hg. After visiting a cardiologist, a clinical, electrocardiographic and echocardiographic (at rest) examination was performed. However, no pathology was found, and therapy was not prescribed. Over the next 3 years, short-term squeezing pain in chest was periodically noted, occurring during fast walking, which was relieved when stopping. In April 2024, the patient was hospitalized in the cardiology department of the University Clinic of the N. A. Semashko Institute of Clinical Medicine of the Russian University of Medicine for an in-depth cardiological examination. Analysis of complaints and anamnestic data, clinical and paraclinical examination, made it possible to diagnose CAD, class III angina pectoris. This was regarded as a late manifestation of cardiotoxicity of chemotherapy in combination with radiation therapy to the mediastinal area, performed at the age of 22 for lymphogranulomatosis. Selective coronary angiography revealed multiple coronary stenoses. For myocardial revascularization, the patient was referred to the I. V. Davydovsky City Clinical Hospital, where 4 drug-eluting stents were inserted. Follow-up monitoring of the cardiovascular system was not carried out. When contacting a cardiologist with complaints typical for coronary insufficiency, CAD was not diagnosed. Conclusion. The presented case shows the difficulties in diagnosing long-term manifestations of cardiotoxicity in the form of premature CAD. It is necessary to conduct additional educational activities and introduce modern technological products to improve the effectiveness of primary prevention, diagnosis and treatment of cardiotoxicity of antitumor therapy.
- Open Access
- 12 May 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 203-208
Vasotoxic Effects of Anticancer Therapy: a Review of Current Data
Cardiovascular and oncological diseases are the leading causes of adult death in the world. Despite proven efficacy, anticancer drugs can cause severe cardiovascular complications. Recently, data have appeared on the possible vasotoxic effects of chemotherapy drugs, which can manifest themselves as the progression of arterial hypertension and atherosclerosis, the development of myocardial ischemia and acute coronary syndrome, the formation of venous and arterial thrombosis. The key mechanism for the development of vasotoxicity is endothelial dysfunction, and anticancer drugs can also affect the processes of thrombosis. The review presents the results of 12 selected observational retro- and prospective studies involving cancer patients receiving presumably vasotoxic therapy. Data on the frequency of occurrence and possibilities for the prevention of vasotoxicity are presented.
- 12 May 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (2) , 203-208
Open AccessVasotoxic Effects of Anticancer Therapy: a Review of Current Data
Cardiovascular and oncological diseases are the leading causes of adult death in the world. Despite proven efficacy, anticancer drugs can cause severe cardiovascular complications. Recently, data have appeared on the possible vasotoxic effects of chemotherapy drugs, which can manifest themselves as the progression of arterial hypertension and atherosclerosis, the development of myocardial ischemia and acute coronary syndrome, the formation of venous and arterial thrombosis. The key mechanism for the development of vasotoxicity is endothelial dysfunction, and anticancer drugs can also affect the processes of thrombosis. The review presents the results of 12 selected observational retro- and prospective studies involving cancer patients receiving presumably vasotoxic therapy. Data on the frequency of occurrence and possibilities for the prevention of vasotoxicity are presented.
- Open Access
- 5 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5258
Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy
Aim. To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker and myocardial cytoprotector.Material and methods. The study included 98 patients with high and very high risk of cardiotoxicity according to the Mayo Clinic scale (USA). Cancer patients with hypertension were offered cardioprotective treatment with a fixed-dose combination of perindopril and bisoprolol, and patients with very high risk and concomitant coronary artery disease additionally trimetazidine.The patients were divided into 2 following groups: the experimental group (n=50), where patients were prescribed cardioprotective therapy, and the control group (n=48), which consisted of patients who refused or had contraindications to cardioprotection. All patients underwent an examination, including the collection of complaints and anamnesis, physical examination, electrocardiography and echocardiography with an assessment of left ventricular (LV) global longitudinal strain before chemotherapy and 1, 3, 6, 9 and 12 months after initiation of anticancer therapy.Results. In patients of the control group, by the end of the follow-up, the left atrial volume index and LV end-diastolic volume index significantly increased. In the main group, these indicators did not change significantly. In the control group, by the final visit, the LV ejection fraction significantly decreased in comparison with the initial value and the value in the first group. After 6, 9 and 12 months, there was a significant decrease in the LV global longitudinal strain in the control group, while in the main group this indicator remained within the normal range. The mortality rate in the control group was significantly higher (15% vs 2% in the experimental group). In the experimental group, cardiotoxic complications occurred in 28%, while in the control group — in 78% of patients.Conclusion. The study demonstrated the significant importance of cardiac monitoring and primary drug prevention of cardiotoxicity of anticancer therapy. A sig nificant deterioration in LV systolic function was shown in patients with a high and very high risk of cardiotoxicity who did not receive cardioprotective therapy, while its high efficiency was demonstrated in patients of the experimental group.
- 5 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5258
Open AccessPotential of primary drug prevention of cardiotoxicity in the context of anticancer therapy
Aim. To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker and myocardial cytoprotector.Material and methods. The study included 98 patients with high and very high risk of cardiotoxicity according to the Mayo Clinic scale (USA). Cancer patients with hypertension were offered cardioprotective treatment with a fixed-dose combination of perindopril and bisoprolol, and patients with very high risk and concomitant coronary artery disease additionally trimetazidine.The patients were divided into 2 following groups: the experimental group (n=50), where patients were prescribed cardioprotective therapy, and the control group (n=48), which consisted of patients who refused or had contraindications to cardioprotection. All patients underwent an examination, including the collection of complaints and anamnesis, physical examination, electrocardiography and echocardiography with an assessment of left ventricular (LV) global longitudinal strain before chemotherapy and 1, 3, 6, 9 and 12 months after initiation of anticancer therapy.Results. In patients of the control group, by the end of the follow-up, the left atrial volume index and LV end-diastolic volume index significantly increased. In the main group, these indicators did not change significantly. In the control group, by the final visit, the LV ejection fraction significantly decreased in comparison with the initial value and the value in the first group. After 6, 9 and 12 months, there was a significant decrease in the LV global longitudinal strain in the control group, while in the main group this indicator remained within the normal range. The mortality rate in the control group was significantly higher (15% vs 2% in the experimental group). In the experimental group, cardiotoxic complications occurred in 28%, while in the control group — in 78% of patients.Conclusion. The study demonstrated the significant importance of cardiac monitoring and primary drug prevention of cardiotoxicity of anticancer therapy. A sig nificant deterioration in LV systolic function was shown in patients with a high and very high risk of cardiotoxicity who did not receive cardioprotective therapy, while its high efficiency was demonstrated in patients of the experimental group.
- Open Access
- 8 December 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (11) , 5244
Atrial fibrillation in a patient with lung cancer: a case report
Introduction. Cancer remains one of the most common causes of death in the world, second only to cardiovascular diseases. The use of novel chemotherapeutic and targeted agents has significantly improved the prognosis of this group of patients. However, this significantly increased the number of cardiotoxic complications of anticancer therapy, including arrhythmias, in particular atrial fibrillation (AF), which negatively affects the prognosis.Brief description. The purpose of this article was to describe the case of a 64-yearold woman with central right lung lower lobe cancer. Upon admission to the chemotherapy department, the patient was first diagnosed with paroxysmal AF. After chemical cardioversion, the first course of multiagent chemotherapy (MAC) was performed as follows: paclitaxel 280 mg and carboplatin 450 mg, which was complicated by the development of recurrent AF episode. During subsequent MAC courses, arrhythmia episodes regularly occurred. During the next AF episode, the patient was hospitalized at the City Clinical Hospital № 51, where she died despite intensive therapy. Postmortem examination ruled out tumor invasion into the left atrium.Discussion. For the AF development, the patient had prerequisites in the form of a significantly remodeled left atrial myocardium. Chemotherapy agents used as antitumor therapy are characterized by the common development of cardiotoxicity, including variety of arrhythmias. The occurrence of AF episodes coincided with the course of MAC, which suggested its cardiotoxic manifestations. Postmortem examination confirmed the high probability of an association between AF episodes and MAC.Conclusion. The presented case illustrates the difficulties encountered by oncologists and cardiologists in determining the genesis and treatment of complex arrhythmias in cancer patients.
- 8 December 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (11) , 5244
Open AccessAtrial fibrillation in a patient with lung cancer: a case report
Introduction. Cancer remains one of the most common causes of death in the world, second only to cardiovascular diseases. The use of novel chemotherapeutic and targeted agents has significantly improved the prognosis of this group of patients. However, this significantly increased the number of cardiotoxic complications of anticancer therapy, including arrhythmias, in particular atrial fibrillation (AF), which negatively affects the prognosis.Brief description. The purpose of this article was to describe the case of a 64-yearold woman with central right lung lower lobe cancer. Upon admission to the chemotherapy department, the patient was first diagnosed with paroxysmal AF. After chemical cardioversion, the first course of multiagent chemotherapy (MAC) was performed as follows: paclitaxel 280 mg and carboplatin 450 mg, which was complicated by the development of recurrent AF episode. During subsequent MAC courses, arrhythmia episodes regularly occurred. During the next AF episode, the patient was hospitalized at the City Clinical Hospital № 51, where she died despite intensive therapy. Postmortem examination ruled out tumor invasion into the left atrium.Discussion. For the AF development, the patient had prerequisites in the form of a significantly remodeled left atrial myocardium. Chemotherapy agents used as antitumor therapy are characterized by the common development of cardiotoxicity, including variety of arrhythmias. The occurrence of AF episodes coincided with the course of MAC, which suggested its cardiotoxic manifestations. Postmortem examination confirmed the high probability of an association between AF episodes and MAC.Conclusion. The presented case illustrates the difficulties encountered by oncologists and cardiologists in determining the genesis and treatment of complex arrhythmias in cancer patients.